GlassScriptPhysician profile
Karen J Dodge
NPI 1669824470
$4,651.50
in general payments reported to CMS, 2019-2025
35 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,747 · 2022: $1,652 · 2023: $746 · 2024: $262 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $755.16 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $731.67 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.09 | 2021-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $444.75 | 2021-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $413.07 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Abbott Laboratories | $307.05 | 2021-2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $165.77 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $123.73 | 2021 | |
| Merck Sharp & Dohme LLC | $123.08 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $108.06 | 2021-2022 | |
| Pfizer INC. | $101.51 | 2021-2023 | |
| Echosens North America, INC. | $86.65 | 2025 | Fibroscan |
| Janssen Pharmaceuticals, INC | $81.57 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $79.97 | 2022 | |
| Amgen INC. | $70.58 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $63.94 | 2021-2025 | Trelegy Ellipta, Rotarix, Pediarix |
| Astellas Pharma US INC | $54.05 | 2023 | Myrbetriq, Veozah |
| Corium, LLC | $49.32 | 2022-2023 | Adlarity |
| Eisai INC. | $47.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.62 | 2022-2023 | |
| Vyera Pharmaceuticals, LLC | $35.08 | 2021 | |
| Esperion Therapeutics, INC. | $31.20 | 2021 | |
| Exact Sciences Corporation | $30.52 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $28.34 | 2021 | |
| Baxter Healthcare | $27.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.91 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.96 | 2025 | Voquezna |
| Mylan Specialty L.P. | $16.92 | 2023 | Yupelri |
| Amarin Pharma, INC. | $15.81 | 2021 | |
| Antares Pharma, INC. | $14.16 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.53 | 2023 | Quviviq |
| Genzyme Corporation | $13.37 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.30 | 2023 | Nuzyra |
| Biogen, INC. | $12.85 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Dodge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.